SANTA CLARA, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone,...
SiBone (NASDAQ:SIBN) raised its full-year 2026 outlook after reporting double-digit revenue growth in the first quarter, with management pointing to new product launches, expanding physician adoption,...
First Quarter 2026 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $52.6 million, representing growth of 11.2% U.S. revenue of $49.3 million, representing...
Barchart Research What to Expect from SIBN Earnings SIBN Generated May 8, 2026 Current Price $12.27 EPS Estimate $$-0.17 Consensus Rating Strong Buy Average Move 9.43% SI-BONE: The Breakthrough Device...
Barchart Research What to Expect from SIBN Earnings SIBN Generated May 8, 2026 Current Price $12.27 EPS Estimate $$-0.17 Consensus Rating Strong Buy Average Move 9.43% SI-BONE: The Breakthrough Device...
Barchart Research What to Expect from SIBN Earnings SIBN Generated May 8, 2026 Current Price $12.27 EPS Estimate $$-0.17 Consensus Rating Strong Buy Average Move 9.43% SI-BONE: The Breakthrough Device...
SANTA CLARA, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone,...
Achieves 20% worldwide revenue growth and positive adjusted EBITDA for Fiscal Year 2025 Generates free cash flow in the Fourth Quarter 2025 SANTA CLARA, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- SI-BONE,...
SANTA CLARA, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone,...
SANTA CLARA, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone,...